| Literature DB >> 33256594 |
Fahimeh Mahmoodi1, Seyedeh Elham Rezatofighi2, Mohammad Reza Akhoond3.
Abstract
BACKGROUND: The emergence of metallo-β-lactamase (MBL)-producing isolates is alarming since they carry mobile genetic elements with great ability to spread; therefore, early detection of these isolates, particularly their reservoir, is crucial to prevent their inter- and intra-care setting dissemination and establish suitable antimicrobial therapies. The current study was designed to evaluate the frequency of antimicrobial resistance (AMR), MBL producers and identification of MBL resistance genes in Escherichia coli strains isolated from fecal samples of the healthy children under 3 years old. A total of 412 fecal E. coli isolates were collected from October 2017 to December 2018. The study population included healthy infants and children aged < 3 years who did not exhibit symptoms of any diseases, especially gastrointestinal diseases. E. coli isolates were assessed to determine the pattern of AMR. E. coli isolates were assessed to determine the pattern of AMR, the production of extended spectrum β-lactamase (ESBL) and MBL by phenotypic methods. Carbapenem-resistant isolates were investigated for the presence of MBL and carbapenemase genes, plasmid profiling, and the ability of conjugation.Entities:
Keywords: Antimicrobial resistance; Carbapenem; Commensal Escherichia coli; Conjugation; Metallo-β-lactamase; NDM; VIM
Mesh:
Substances:
Year: 2020 PMID: 33256594 PMCID: PMC7708168 DOI: 10.1186/s12866-020-02051-8
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Frequency of AMR, MDR, and ESBL among commensal E. coli strains isolated from children in Khuzestan and Fars provinces
| CHL | NA | AMP | TET | KAN | CTX | CAZ | STR | SXT | CIP | GEN | IMP | MEN | MDR | ESBL | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23 (11.4) | 88 (43.8) | 130 (64.7) | 85 (42.3) | 18 (9) | 100 (49.8) | 82 (40.8) | 81 (40.3) | 101 (50.2) | 51 (25.4) | 13 (6.5) | 4 (2) | 4 (2) | 108 (53.7) | 31 (15.42) | |
| 15 (7.1) | 36 (17.1) | 52 (24.6) | 37 (17.5) | 7 (3.3) | 51 (24.2) | 33 (15.6) | 27 (12.8) | 32 (15.2) | 11 (5.2) | 4 (1.9) | 2 (0.9) | 2 (0.9) | 41 (19.4) | 17 (8.06) | |
| 38 (9.2) | 124 (31.1) | 182 (44.2) | 122 (29.6) | 25 (6.1) | 151 (36.7) | 115 (27.9) | 108 (26.2) | 133 (32.3) | 62 (15) | 17 (4.1) | 6 (1.5) | 6 (1.5) | 149 (36.2) | 48 (11.7) |
a(Star): Statistically significant. P < 0.05; CHL Chloramphenicol, NA Nalidixic-acid, AMP Ampicillin, TET Tetracycline, KAN Kanamycin, CTX cefotaxime, CAZ ceftazidime, STR Streptomycin, STX sulfamethoxazole-trimethoprim, CIP ciprofloxacin, GEN Gentamycin, IMP Imipenem, MEN Meropenem, MDR Multi-drug resistance, ESBL Extended-spectrum beta-lactamases
Frequency of AMR and MDR by age among commensal E. coli strains isolated from children in Khuzestan and Fars provinces
| Age (Year) | Total number | CHL | NA | AMP | TET | KAN N (%) | CTX | CAZ | STR | SXT | CIP | GEN N (%) | IMP N (%) | MEN N (%) | MDR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 130 | 7 (5.4) | 33 (25.4) | 47 (36.1) | 28 (21.5) | 7 (5.4) | 31 (23.8) | 27 (20.8) | 27 (20.8) | 32 (24.6) | 20 (15.4) | 6 (4.6) | 1 (0.8) | 1 (0.8) | 34 (26.1) | |
| 144 | 12 (8.3) | 38 (26.4) | 60 (41.7) | 44 (30.5) | 8 (5.5) | 51 (35.4) | 41 (28.5) | 37 (25.7) | 45 (31.2) | 14 (9.7) | 3 (2) | 1 (0.7) | 1 (0.7) | 47 (32.6) | |
| 138 | 19 (13.8) | 53 (38.4) | 73 (52.9) | 51 (37) | 10 (7.2) | 69 (50) | 47 (34.05) | 44 (31.9) | 55 (40) | 28 (20.3) | 8 (5.8) | 4 (2.9) | 4 (2.9) | 65 (47.1) | |
| – | 0.382–0.919 | 0.570–0.968 | 0.582–0.948 | 0.537–0.916 | – | 0.431–0.725 | 0.546–0.940 | 0.567–0.986 | 0.550–0.927 | – | – | – | – | 1.230–2.056 | |
| – | 0.593 | 0.743 | 0.743 | 0.701 | – | 0.559 | 0.716 | 0.748 | 0.714 | – | – | – | – | 1.591 | |
| – | 0.019 | 0.028 | 0.017 | 0.009 | 0.521 | 0.001> | 0.016 | 0.039 | 0.011 | 0.247 | 0.609 | 0.162 | 0.162 | 0.001> |
a(Star): Statistically significant. P < 0.05; OR Odds Ratio, CI Confidence Interval, CHL Chloramphenicol, NA Nalidixic-acid, AMP Ampicillin, TET Tetracycline, KAN Kanamycin, CTX cefotaxime, CAZ ceftazidime, STR Streptomycin, STX sulfamethoxazole-trimethoprim, CIP ciprofloxacin, GEN Gentamycin, IMP Imipenem, MEN Meropenem, MDR Multi-drug resistance
Frequency of AMR and MDR by sex among commensal E. coli strains isolated from children in Khuzestan and Fars provinces
| Sex (N) | CHL | NA | AMP | TET | KAN N (%) | CTX | CAZ | STR | SXT | CIP | GEN N (%) | IMP N (%) | MEN N (%) | MDR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 (8.3) | 68 (31.5) | 100 (46.3) | 70 (32.4) | 16 (7.4) | 86 (39.8) | 64 (29.6) | 64 (29.6) | 74 (34.3) | 35 (16.2) | 10 (4.6) | 4 (2) | 4 (2) | 84 (38.9) | |
| 20 (10.2) | 56 (28.6) | 82 (41.8) | 52 (26.5) | 9 (4.6) | 65 (33.2) | 51 (26) | 44 (22.4) | 59 (30.1) | 27 (13.8) | 7 (3.6) | 2 (0.9) | 2 (0.9) | 65 (33.2) | |
| 38 (9.2) | 124 (31.1) | 182 (44.2) | 122 (29.6) | 25 (6.1) | 151 (36.7) | 115 (27.9) | 108 (26.2) | 133 (32.3) | 62 (15) | 17 (4.1) | 6 (1.5) | 6 (1.5) | 149 (36.2) |
CHL Chloramphenicol, NA Nalidixic-acid, AMP Ampicillin, TET Tetracycline, KAN Kanamycin, CTX cefotaxime, CAZ ceftazidime, STR Streptomycin, STX sulfamethoxazole-trimethoprim, CIP ciprofloxacin, GEN Gentamycin, IMP Imipenem, MEN Meropenem, MDR Multi-drug resistance
Pattern of antimicrobial resistance, MBLs genes, carbapenemase genes, and phenotypic characterization of commensal E. coli isolates resistant to imipenem
| No of isolate | Age (month) | CHL | NA | AMP | TET | KAN | CTX | CAZ | STR | STX | CIP | GEN | IMP | MEN | MDR | DDST | CDT | PBA | MHT | mCIM | eCIM | MBL | Transconjugation | MIC | Size of plasmids (kb) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 260 | 12 | R | R | R | S | R | R | R | R | R | R | S | R | R | + | – | – | – | + | + | + | + | 6 | 3P > 23 | ||||||||||||
| 271 | 36 | R | S | R | S | S | R | R | S | S | S | S | R | R | – | + | – | – | + | + | + | + | 6 | 2P > 23 | ||||||||||||
| 335 | 35 | S | R | R | R | R | R | R | R | R | R | S | R | R | + | – | – | – | + | + | + | + | 5 | 12, 3P > 23 | ||||||||||||
| 175 | 22 | S | R | S | R | R | R | S | R | S | I | I | R | R | – | – | – | – | + | – | – | – | 6 | 16, 12, 1P > 23 | ||||||||||||
| 176 | 36 | S | R | R | S | S | R | R | R | S | S | S | R | R | – | – | – | – | + | + | + | + | 6 | 16, 12 | ||||||||||||
| 317 | 31 | S | R | R | R | I | R | R | R | R | R | S | R | R | – | – | + | – | + | – | – | + | 6 | 5, 14 |
CHL Chloramphenicol, NA Nalidixic-acid, AMP Ampicillin, TET Tetracycline, KAN Kanamycin, CTX cefotaxime, CAZ ceftazidime, STR Streptomycin, STX sulfamethoxazole-trimethoprim, CIP ciprofloxacin, GEN Gentamycin, IMP Imipenem, MEN Meropenem, MDR Multi-drug resistance, ESBL Extended-spectrum beta-lactamases, DDST Double disc synergy test, CDT Combined disc test, PBA Phenylboronic acid, MHT Modified Hodge test, mCIM Modified carbapenem inactivation method, eCIM EDTA-CIM, MBL metalo-beta-lactamase, MIC Minimum inhibitory concentration, P plasmid
Names and sequences of primers used in this study
| Primer name | Sequence (5′ → 3′) | References |
|---|---|---|
| ACCGCAGCAGAGTCTTTGCC | [ | |
| ACAACCAGTTTTGCCTTACC | ||
| GTTTTATGTGTATGCTTCC | [ | |
| AGCCTGTTCCCATGTAC | ||
| AGTGGTGAGTATCCCGACAG | [ | |
| ATGAAAGTGCGTGGAGAC | ||
| ATGTTCAAACTTTTGAGTAAG | [ | |
| CTACTCAACGACTGAGCG | ||
| GCGTTTTGTTTGTTGCTC | [ | |
| TTGGGGATGTGAGACTAC | ||
| TCGACACACCTTGGTCTG | [ | |
| AACTTCCAACTTTGCCAT | ||
| TACAAGGGATTCGGCATCC | [ | |
| TAATGGCCTGTTCCCATG | ||
| GGCGGAATGGCTCATCACGA | [ | |
| CGCAACACAGCCTGACTTTC | ||
| ‘ATGTCACTGTATCGCCGTCT | [ | |
| ‘TTTTCAGAGCCTTACTGCCC | ||
| AAGCATGATGAGCGCAAAG | [ | |
| AAAAGGCCCATTTATCTCAAA | ||
| TTGGTGGCATCGATTATCGG | [ | |
| GAGCACTTCTTTTGTGATGGC | ||
| CCGATACGCTGCCAATCAGT | [ | |
| ACGCAGACCGTAGGCCAGAT |